Entasis Therapeutics logo

Entasis Therapeutics(NASDAQ) ETTX

This security has been delisted. This page is retained for historical reference.

Entasis Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.192022-07-08
Entasis Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 2.192022-07-01
1 month+0%USD 2.192022-06-08
3 month+18.38%USD 1.852022-04-08
Year to date+0%USD 2.192021-12-31
1 year-11.16%USD 2.472021-07-08
3 year-66.05%USD 6.452019-07-09
Since inception-79.46%USD 10.662018-09-26

ETTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

ETTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-112.91%

Return on Capital

-151.03%

Return on Assets

-115.20%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$89.29M

EBITDA

-$86.71M

Operating Cash Flow

-$46.62M

Capital Expenditure

-$68.00K

Free Cash Flow

-$46.69M

Cash & ST Invst.

$33.55M

Total Debt

$18.85M

Entasis Therapeutics Performance Analysis

Entasis Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
Entasis Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22021-06-30N/A
Q32021-09-30N/A
Q42021-12-31N/A
Q12022-03-31N/A
Entasis Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.09N/A
Entasis Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22021-06-30N/A
Q32021-09-3010.3%
Q42021-12-31-284.6%
Q12022-03-3168.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

51

N/A

Net Income

-$15.27M

-42.7%

EBITDA

-$15.23M

-42.7%

Quarterly Fundamentals

Name
Q1 2022YOY CHG

Total Cash

$33.55M

-25.3%

Total Debt

$18.85M

+1507.3%

Accounts Receivable

$1.15M

-55.2%

Inventory

$0.00

N/A

Long Term Debt

$3.30M

+516.6%

Short Term Debt

$15.56M

+2338.1%

Return on Assets

-1.15%

N/A

Return on Invested Capital

-1.51%

N/A

Free Cash Flow

-$13.76M

-36.1%

Operating Cash Flow

-$13.75M

-36.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLVXHilleVax, Inc.
$2.09-0.48%
JNCEJounce Therapeutics, Inc.
$1.88+0.00%
CYTCyteir Therapeutics, Inc.
$3.02-2.27%
OPNTOpiant Pharmaceuticals, Inc.
$20.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.88-0.04%
INTCIntel
$106.18+0.02%
NOKNokia
$10.81+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.54+0.00%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.